Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012)

Vertex Pharmaceuticals' (VRTX) quarterly Finished Goods came in at $23.3 million in Q3 2012, up 94.18% year-on-year from $12.0 million in Q4 2011, and down 0.81% quarter-over-quarter from $23.5 million in Q2 2012.

Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012) Analysis & Trends

Vertex Pharmaceuticals' Finished Goods history runs 2 years deep, the most recent figure standing at $23.3 million for Q3 2012.

  • On a quarterly basis, Finished Goods rose 94.18% year-over-year to $23.3 million in Q3 2012; TTM through Sep 2012 was $23.3 million, a 94.18% increase from a year earlier, with the FY2011 full-year figure at $33.2 million, changed N/A from the prior year.
  • Finished Goods slipped to $23.3 million in Q3 2012 per VRTX's latest filing, from $23.5 million in the prior quarter.
  • Across five years, Finished Goods topped out at $33.2 million in Q4 2011 and bottomed at $12.0 million in Q3 2011.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn

Historic Data

Download Data
DateValue
Sep 30, 2012 23.32 Mn
Jun 30, 2012 23.51 Mn
Mar 31, 2012 26.35 Mn
Dec 31, 2011 33.21 Mn
Sep 30, 2011 12.01 Mn